Elective pelvic irradiation in stage A2, B carcinoma of the prostate: analysis of RTOG 77-06.
From 1978 to 1983 the Radiation Therapy Oncology Group conducted a study to evaluate the role of elective pelvic lymph node irradiation in carcinoma of the prostate. Eligible patients were those with clinical Stage A2 (occult disease with more than 3 positive chips and poorly differentiated tumor) and Stage B without clinical (lymphangiogram) or biopsy evidence of lymph node involvement. The patients were randomized to receive 6.5 weeks of either prostatic bed irradiation only 6500 cGy at 180-200 cGy per treatment or pelvic node irradiation to 4500 cGy with a boost of 2000 cGy to the prostatic bed bringing the total dose to 6500 cGy. As of February, 1988, the median follow up has been 7 years and there were 445 analyzable cases who were evaluated for local control, incidence of distant metastases, ned (no evidence of disease) survival and survival. The results of the study revealed no statistically significant benefit of elective pelvic irradiation.
Asbell
S O
SO
Albert Einstein Medical Center, Department of Radiation Therapy, Philadelphia, PA 19141.
Krall
J M
JM
Pilepich
M V
MV
Baerwald
H
H
Sause
W T
WT
Hanks
G E
GE
Perez
C A
CA
D000368:Aged; D002985:Clinical Protocols; D002986:Clinical Trials as Topic; D006801:Humans; D008198:Lymph Nodes / Q000528:radiation effects*; D008297:Male; D008875:Middle Aged; D015337:Multicenter Studies as Topic; D009362:Neoplasm Metastasis; D009364:Neoplasm Recurrence, Local; D010388:Pelvis; D011471:Prostatic Neoplasms / Q000401:mortality / Q000473:pathology / Q000532:radiotherapy*; D011897:Random Allocation; D014481:United States